EP2101598A2 - Tabakprodukt sowie herstellung und verwendungen davon - Google Patents

Tabakprodukt sowie herstellung und verwendungen davon

Info

Publication number
EP2101598A2
EP2101598A2 EP08702112A EP08702112A EP2101598A2 EP 2101598 A2 EP2101598 A2 EP 2101598A2 EP 08702112 A EP08702112 A EP 08702112A EP 08702112 A EP08702112 A EP 08702112A EP 2101598 A2 EP2101598 A2 EP 2101598A2
Authority
EP
European Patent Office
Prior art keywords
cyclodextrin
derivative
product
tobacco
flavourant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP08702112A
Other languages
English (en)
French (fr)
Other versions
EP2101598B1 (de
Inventor
Peter Clayton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British American Tobacco Investments Ltd
Original Assignee
British American Tobacco Investments Ltd
British American Tobacco Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British American Tobacco Investments Ltd, British American Tobacco Co Ltd filed Critical British American Tobacco Investments Ltd
Publication of EP2101598A2 publication Critical patent/EP2101598A2/de
Application granted granted Critical
Publication of EP2101598B1 publication Critical patent/EP2101598B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18Treatment of tobacco products or tobacco substitutes
    • A24B15/28Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B13/00Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18Treatment of tobacco products or tobacco substitutes
    • A24B15/28Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/281Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
    • A24B15/283Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances

Definitions

  • the invention relates generally to smokeless tobacco, tobacco derivative or tobacco substitute products incorporating cyclodextrins or cyclodextrin derivatives. More specifically, the invention relates to smokeless tobacco, tobacco derivatives, or tobacco substitute products comprising cyclodextrins or cyclodextrin derivatives which are incorporated in or bound to a cellulosic material.
  • Cyclodextrins are cyclic oligosaccharides consisting of 1,4- ⁇ -glucoside monomers. They exist naturally as ⁇ -, ⁇ -, and ⁇ -cyclodextrins consisting of 6, 7, and 8 glucose monomers in a ring, respectively. Their respective internal diameters are 0.57, 0.78, and 0.95 nm; each has a torus depth of about 0.78 nm.
  • the toriod shape offers unequal opening sizes for the inner cavity. The smaller opening exposes a primary hydroxyl group to the surrounding solvent while the larger opening exposes a secondary hydroxyl group. The presence of these hydroxyl groups results in the exterior surface of the toroidal shaped molecule having a hydrophilic character, while the interior of the toroid is less hydrophilic and may be considered as a hydrophobic cavity.
  • the interior of the toroid can host hydrophobic molecules, or hydrophobic chemical moieties, while the exterior allows the complex to be solubilised in an aqueous environment.
  • hydrophobic molecules or moieties can be used to form strong inclusion complexes with cyclodextrins or cyclodextrin derivatives.
  • aqueous solubility of vanillin is much higher in the presence of ⁇ -cyclodextrin, present at a molecular ratio of 1:1, compared to when ⁇ -cyclodextrin is absent from the solution (Karathanos et al. Food Chemistry 101, pp 652-658).
  • Cyclodextrin derivatives are also widely used.
  • 2-hydroxypropyl- ⁇ - cyclodextrin is used to formulate drug complexes which facilitate the aqueous solubility of certain pharmaceutically-active compounds.
  • One application for cyclodextrin derivates is to complex them with nicotine then incorporate that complex into chewing gum, providing a smoking cessation aid as described in WO 91/09599.
  • a chewing gum could alternatively offer flavour complexed in the cyclodextrin.
  • Another use of cyclodextrins and derivatives thereof complexed with flavour particles is their application to smoking products.
  • Flavourant use is common in the tobacco field, a wide variety of flavourants are known and flavours are continually being developed.
  • Flavourants are traditionally added to whole tobacco, reconstituted tobacco, wrapping paper, cigarette filters, or packaging, often to affect the flavour of the product in use but also to improve the aroma of the unused product or that experienced by persons in the vicinity of the product during use.
  • One manufacturing and packaging challenge presented by many known flavourants is that they tend to be highly volatile and easily sublime.
  • One solution has been to complex the flavourant with a cyclodextrin.
  • US 5,144,964 proposes a water-soluble molecular inclusion complex of a ⁇ -cyclodextrin derivative and a lipophilic organic flavourant compound which can be incorporated in the wrapping paper for a cigarette.
  • a smokeless oral tobacco product which comprises at least one of tobacco, a tobacco derivative, or a tobacco substitute and a cellulosic material.
  • the cellulosic material comprises at least one cyclodextrin or cyclodextrin derivative.
  • the tobacco can be encapsulated in a cellulosic wrapper.
  • the cellulosic material may be, for example, fibrous, a woven web, or a non-woven web.
  • the cyclodextrin or cyclodextrin derivative may be chemically attached to the cellulosic material.
  • a spacer group may be located between the cellulosic material and the cyclodextrin or cyclodextrin derivative.
  • a complex agent may be complexed with the cyclodextrin or cyclodextrin derivative, such complex agent being any agent which can be located in the cavity of the cyclodextrin or cyclodextrin derivative or otherwise provided in or on such as by chemical bonding. Examples of complex agent include flavourants, aroma modifiers, and antimicrobial agents.
  • Flavourants can comprise monoterpene flavourant, monoaromatic flavourant, or polyaromatic flavourant, and examples include (+), (-)-limonene, cinnamaldehyde, cinnamonitrile, euginol, cis-isoeuginol, trans-isoeuginol, eugenyl acetate, eugenol methyl/ethyl esters, trans-anethole, cis-anethole, menthol, isomenthol, neomenthol, (+)-menthone, (-)-menthone, (+)-citronellal, S(+)-carvone, R(-)-carvone, trans- methyl cinnamate, cis-methyl cinnamate, vanillin, capsaicin, phenylpropanoids, aspartame, chocolate, coffee, pyrazines, salt, ⁇ -Glu-Tyr, ⁇ -Glu-Phe,
  • Aroma modifiers can comprise, for example, maltol, ethyl maltol, cis-jasmone, methyl jasmonate, geraniol, nerol, geranyl esters, neryl esters, (+)-citronellol, (-)- citronellol, citral, (+)-limonene, (-)-limonene, and monoterpenes.
  • An example of an antimicrobial agent is hinokitol.
  • a cyclodextrin or cyclodextrin derivative is used in the preparation of a smokeless oral tobacco product, wherein the product comprises tobacco.
  • a cyclodextrin or cyclodextrin derivative complexed with at least one flavourant can be used in the preparation of a smokeless oral tobacco product, wherein the product comprises tobacco.
  • the product can further comprise a cellulosic material, in which case the cyclodextrin or cyclodextrin derivative is complexed to the cellulosic material such as by chemical attachment.
  • a method for complexing at least one cyclodextrin or cyclodextrin derivative with a material in or formed by a smokeless oral tobacco product comprises the steps of providing a smokeless oral tobacco product comprising at least one cyclodextrin or cyclodextrin derivative, contacting the product with moisture to moisten the product, and allowing the material to complex with the cyclodextrin or cyclodextrin derivative.
  • the cyclodextrin or cyclodextrin derivative comprises at least one flavourant
  • the method can further comprise the step of allowing the flavourant to be released from the cyclodextrin or cyclodextrin derivative after the contacting step.
  • materials complexed according to this embodiment include benzo(a)pyrene and cadmium.
  • cellulosic material means a material consisting wholly or in part of natural or synthetic cellulose (C 6 H 10 O 5 ) n , a long chain polymeric polysaccharide carbohydrate of ⁇ -glucose, for example lignocellulose, flax fibres, hardwood pulp, softwood pulp, hemp fibres, esparto fibres, kenaf fibres, jute fibres, and sisal fibres. It also means a material consisting wholly or in part of cellulose derivates, wherein the hydroxy! groups of cellulose have been partially or fully reacted with any appropriate entity. Examples of derivatives include cellulose esters such as cellulose acetate or cellulose triacetate. The term also encompasses mixtures of more than one type of cellulosic material as well as materials which have undergone treatments to improve performance or appearance, such as bleaching.
  • Cyclodextrin(s) "cyclodextrin derivative” or “CD” means any molecule from the class of naturally-occurring or synthetic cyclodextrins. It further encompasses molecules or portions thereof derived from cyclodextrins or synthesized to resemble cyclodextrins in whole or in part. Such cyclodextrins or cyclodextrin derivatives are toroidal, chiral structures having a hydrophilic, water-soluble outer surface comprising hydroxyl groups and a less hydrophilic or hydrophobic internal cavity.
  • a cyclodextrin as denoted herein could refer to an ⁇ , ⁇ or ⁇ cyclodextrin, a methyl substituted cyclodextrin, an ethyl substituted cyclodextrin , an alkyl substituted cyclodextrin with straight chain or branch chain alkyl groups, a hydroxyalkyl substituted cyclodextrin (e.g. 2-hydroxypropyl cyclodextrin , an anionic cyclodextrin, a cationic cyclodextrin, a quaternary ammonium cyclodextrin, an amphoteric cyclodextrin, or mixture of the same).
  • a hydroxyalkyl substituted cyclodextrin e.g. 2-hydroxypropyl cyclodextrin , an anionic cyclodextrin, a cationic cyclodextrin, a quaternary ammonium
  • “Flavour” or “Flavourant” refers to any compound or chemical entity which may stimulate a taste sensation when consumed or when placed in the oral cavity of a user. Stimulation may be in the form of actual taste stimulation or perceived taste stimulation (simulation), such as that provided by scented materials.
  • flavours include but are not limited to citrus ((+), (-)-limonene), fruit (benzaldehyde) aromatic and spice (cinnamon could be cinnamaldehyde, green leafy odour could be cis-3-hexenal, clove could be euginol, other monoterpene flavourants), mint (mentha flavours such as menthol, isomenthol, neomenthol), pepper (S(+)-carvone), dill (R(-)-carvone), ginger (phenylpropanoids), vanilla (vanillin and other aromatic aldehydes), sweet (sweeteners such as aspartame), chocolate and coffee (pyrazines), liquorice, salt ( ⁇ -Glu-Tyr, ⁇ -Glu-Phe, orinithyl containing peptides).
  • Flavourants which can achieve desired flavours can be natural or synthetic and include but are not limited to the above examples.
  • aroma modifier compounds may be complexed to cyclodextrins according to the invention.
  • aroma modifiers include but are not limited to maltol and ethyl maltol, cis-jasmone, methyl jasmonate, geraniol, nerol, geranyl and neryl esters, (+)- citronellol, (-)-citronellol, citral, (+)-limonene, (-)-limonene, monoterpene aroma compounds.
  • flavourants it can be possible to provide not only a product with improved flavour, but also one which has additional benefits over existing products.
  • flavourants which mimic the taste of salt can be used to provide a reduced salt product
  • artificial sweeteners can be used to provide a reduced calorie product.
  • flavourants in addition to or instead of flavourants other complex agents can be provided with the cyclodextrins of the present invention.
  • an anti-microbial agent such as hinokitol can increase shelf-life and/or provide a product which can be suitably stored under less stringent conditions.
  • Complex agents such as anti- refrigerants or preservative agents could be used to improve product stability and/or minimize undesired limitations on storage and transport conditions.
  • the complex agents used with the present invention thus give the blender greater latitude in the use of flavourants, buffers, additives and moisture when preparing the tobacco or tobacco substitute.
  • Smokeless oral tobacco products are a class of tobacco products which are intended for oral administration. Such products are inserted in the mouth of the user and retained for a period of time, often for between 5 and 60 minutes. The product may be actively chewed or allowed to remain in the mouth without mastication. The user may expectorate saliva during use or not.
  • the tobacco portion may comprise loose tobacco leaves or leaves which are chopped, shredded, or pulverized, alternatively, the tobacco may be compressed into a plug. Chopped, shredded or pulverized tobacco may be provided in a pouch, which pouch is inserted orally.
  • smokeless oral tobacco product is used herein to denote any tobacco product which is not intended for combustion but instead designed to be placed in the oral cavity of a user for a limited period of time, during which there is contact between the user's saliva and the product.
  • the term encompasses conventional products such as Swedish-style snus and American-style chewing tobacco, as well as less conventional and forthcoming products.
  • Spacer group or "SG” is used herein to describe any of a class of molecules which can be used to create a physical or chemical span between a cyclodextrin and cellulosic material. Spacer entities are well known in the art; see, for example, WO 06/53628.
  • spacer entities examples include (CH 2 ) and (CH 2 CH 2 O) where p is an integer from 2 to 6 and q is an integer from 1 to 3.
  • the spacer group could be an imidazolidone moiety or (CH 2 ) r or (CH 2 O) 1 where r is an integer between 1 and 5.
  • tobacco, tobacco derivative, or tobacco substitute as used herein includes pure tobacco and reconstituted tobacco. It includes derivatives of tobacco such as specific compounds, e.g., nicotine, whether extracted from actual tobacco or otherwise produced, as well as structural derivatives such as the fibrous portion of a tobacco leaf. Tobacco substitutes can comprise individual chemical entities as well as complex chemical solutions which, when appropriately prepared, physically resemble actual tobacco.
  • the invention is directed to smokeless oral tobacco products which incorporate at least one cyclodextrin or cyclodextrin derivative.
  • Smokeless oral tobacco products particularly those comprising natural tobacco, contain compounds or release compounds in use that may present a risk of injury to the user after extensive and extended use of the product. Technologies for identifying and extracting such compounds from the natural tobacco have progressed; however, it can be preferable, perhaps particularly so for newly- identified compounds, to provide a way to remove the compounds during use of the product so as to minimize the complex steps related to preparing the tobacco for inclusion in a product.
  • the cyclodextrins of the present invention thus provide a novel means for complexing with potentially harmful compounds, before the compounds can be carried away with the user's saliva and move freely about the oral cavity. It is therefore advantageous to provide the cyclodextrins in a manner so that they are bound to one or more substrates that will be expectorated after use of the product, thereby removing the cyclodextrin-compound complex from the mouth of the user.
  • cyclodextrins are attached, for example by chemical bonds, to cellulosic material. That material is then incorporated into the smokeless oral tobacco product, e.g., a filler material or as a wrapper for a pouch-like product. Attachment of cyclodextrins is a routine matter, technology related to their applicability in chromatography provide numerous examples of the process.
  • a spacer group can be provided. This ensures the cavity of the cyclodextrin is free to interact with the surrounding solution either to release a complexed compound or to remove a target molecule from free solution.
  • Cyclodextrins are known in the art, as are methods and materials for selecting particular cyclodextrins based on the molecule to be contained within the cavity. For example, in use it can be expected that certain smokeless oral tobacco products release polyaromatic hydrocarbons such as benzo(a)pyrene, a molecule which is suspected of potentially causing harm for long-term heavy users.
  • Benzo(a)pyrene has been calculated to be 0.88 nm across its wide axis. It is thought that benzo(a)pyrene cannot form an inclusion complex with ⁇ -cyclodextrin, but that it forms a stable 1 :1 host-guest complex with ⁇ - cyclodextrin and a 1 :2 host-guest complex with ⁇ - cyclodextrin (Fielden and Packham, J.Chromatog. 516(1990) 355- 364).
  • benzo(a)pyrene To remove benzo(a)pyrene from a product during use it can be preferred to take advantage of its high propensity to complex within the ⁇ -cyclodextrin cavity. Once complexed, benzo(a)pyrene is unlikely to return to free solution, i.e., the user's saliva, as it is an extremely hydrophobic molecule.
  • free solution i.e., the user's saliva
  • free solution i.e., the user's saliva
  • the invention further provides complexing the cyclodextrins with one or more flavourants which will be released by the cyclodextrin during use, after which the cyclodextrins present an empty cavity for complexing with a compound of interest present or generated in the tobacco portion of the product.
  • This provides the added benefit of flavour release while still reaping the benefit of reducing the release of certain compounds into the oral cavity of the user.
  • flavourants or other additives which are also within the scope of the invention, are small mono- aromatic compounds which form transient complexes with cyclodextrins and are readily released upon contact with moisture such as saliva, ⁇ -cyclodextrin presents a large cavity from which a small compound would more rapidly disassociate, providing an open cavity into which another molecule such as benzo(a)pyrene could complex.
  • ⁇ -cyclodextrin could be a preferred cyclodextrin for the complexation of flavourants and aroma molecules because it presents a cavity size which is ideal for a large number of flavourant and aroma molecules.
  • the bi-aromatic ring compounds in particular would be held stably in the cyclodextrin complex until conditions are such that they solubilize. This would allow for a high moisture content in the product which would not interfere with the inclusion complex, only upon use where the user's saliva causes a much higher degree of wetting would sufficient solution be available to release the flavourant.
  • the cyclodextrins would then be free to complex with other compounds.
  • Particularly drawn to the cyclodextrins would be hydrophobic molecules such as those which might potentially cause harm to the user if allowed to pass into the saliva and be carried around the oral cavity freely.
  • Another feature of the invention is that molecules complexed by cyclodextrins are presumably more resistive to decomposition, degradation and alteration. It is known, for example, that the propensity for the flavourant vanillin to undergo oxidation is lowered while it is complexed to a cyclodextrin.
  • ⁇ -cyclodextrins could preferably be used where the flavourant of interest is a small molecule, such as a mono-aromatic flavour compound containing one phenyl-sized moiety, for example, phenylacetaldehyde dimethyl acetal. Release from the inclusion complex would be slow and sustained over a period corresponding to the average time of product use.
  • benzo(a)pyrene is known to be present in certain smokeless tobacco products in amounts ranging from approximately 0.1-10 ⁇ g/kg (e.g., a product with l ⁇ g/kg could release 4 mmole/kg into the user's mouth). So where a 1:1 complex between benzo(a)pyrene and a cyclodextrin is assumed, and no other molecule is believed to complex with the cyclodextrin, 0.4-40 mmole/kg cyclodextrin could be provided in an effort to complex all benzo(a)pyrene from the product.
  • cyclodextrins To compensate for less than efficient complexing and the possibility of other molecules forming complexes with certain of the cyclodextrins, one may choose to use, for example, ten or twenty times the base amount of cyclodextrin calculated, in this example, 4.0-800 mmole/kg.
  • the ratio of cellulosic material to tobacco is eminently variable, the amount of cyclodextrin relative to the tobacco and tobacco constituents can easily be manipulated.
  • the cellulosic material may be provided, e.g., as fragments, fibres, leaves or sheets blended in the tobacco or as a moisture-permeable wrapper encapsulating the tobacco.
  • Cyclodextrins may be provided interstitially within or bonded to the cellulosic material in a random pattern or in a specific pattern such as rows. Where the cellulosic material forms a wrapper for a tobacco pouch, the cyclodextrins may be provided on the side of the pouch facing the user or the side facing the tobacco during use, or a mixture of both. Methods of providing the cyclodextrins in the cellulosic material as well as densities, locations and the like can be optimized depending on factors such as the molecule the cyclodextrin is designed to capture and its relative amounts in the product, how and where that molecule is released, the timing of the release, and the like.
  • flavourants or other additives are provided as an inclusion complex with cyclodextrins, they may be provided in a range such that perhaps about 5% of the cyclodextrins are complexed, or 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% are complexed.
  • a smokeless oral tobacco product may incorporate all of its flavourant or additive in the cyclodextrin complex, or only a portion of its overall flavourant or additive may be present in complex with cyclodextrin and the remainder provided according to conventional means.
  • cyclodextrin immobilized on a cellulosic wrapper may include 0.85 mol/mol (+)-limonene or 0.95 mol/mol hinokitiol.
  • a variety of conditions can be used to attach ⁇ -, ⁇ -hydroxypropyl, and/or ⁇ - cyclodextrins to cellulose powder via a spacer or linker group.
  • Example 1 Cyclodextrin linked to Cellulose Powder with Epichlorohydrin Two samples were prepared using aqueous potassium carbonate to attach epichlorohydrin and cyclodextrin to cellulose.
  • a mixture of cellulose (5Og), epichlorohydrin (5g), potassium carbonate (1Og) and ⁇ - cyclodextrin (1Og) in water (200ml) were stirred at 50 0 C for 5 hours. The mixture was cooled, filtered, washed exhaustively with water and dried in vacuo to give the first sample, PD906 (50.Ig).
  • the second sample was prepared by stirring a mixture of cellulose (5Og), epichlorohydrin (5g), potassium carbonate (1Og) and ⁇ - cyclodextrin (1Og) in water (200ml) at 75°C for 14 hours. The mixture was cooled, filtered, washed exhaustively with water and dried in vacuo to give sample PD907 (5Og).
  • sample PD913 (49.4g).
  • the second sample of this type was created when a mixture of cellulose (5Og), epichlorohydrin (7g), sodium hydroxide (6g) and ⁇ -cyclodextrin (1Og) in water (200ml) were stirred at 50 0 C for 2 hours then at room temperature overnight. The mixture was cooled, filtered, washed exhaustively with water (very slow filtration) and dried in vacuo to yield sample PD913 (49.4g).
  • the second sample of this type was created when a mixture of cellulose (5Og), epichlorohydrin (7g), sodium hydroxide (6g) and ⁇ -cyclodextrin (1Og) in water (200ml) were stirred at 50 0 C for 2 hours then at room temperature overnight. The mixture was cooled, filtered, washed exhaustively with water (very slow filtration) and dried in vacuo to give sample PD914 (50.8g).
  • the mixture was pre-dried in vacuo at 75°C before heating under nitrogen in an oil bath up to 175°C (oil bath temperature) in a magnetically stirred glass flask for 20 minutes. Cooled, washed exhaustively with water and dried in vacuo at 65- 75°C.
  • the dried paste was slurried in methanol (150ml), dried at 60 0 C in vacuo, then heated under nitrogen in a 175°C oil bath for 20 minutes.
  • the sample produced was PD917B (49g).
  • Tanning was observed for most of the thermal reactions - the least coloured samples from those described above were PD916 and PD919.
  • a feature of the invention was displayed using derivatised cellulose to remove B(a)P from an aqueous solution. This also had the effect of confirming the variety of cyclodextrin entities described above were successfully bound to cellulose.
  • mini-columns containing a bed of either the cyclodextrin derivatised cellulose or pure cellulose were prepared.
  • a small quantity of a solution of B(a)P in acetonitrile was placed at the head of this column followed by larger amounts of water. The water was allowed to flow through the column without assistance under gravity and the resultant eluent was collected and analysed for B(a)P.
  • Reverse phase HPLC was used with Fluorescence detection.
  • the column used was 125 x 4.60 mm 5 micron (Envirosep PP, Phenomenex), thermostated at 30°C.
  • the mobile phase was water/acetonitrile proportioned under the gradient regime detailed in Table 2.
  • PD917A was a gamma hydroxypropyl cyclodextrin cellulose derivative
  • PD908 was a beta cyclodextrin cellulose derivative
  • PD909 was a gamma cyclodextrin cellulose derivative
  • PD912 was a beta cyclodextrin cellulose derivative.
  • sample PD917A supports the particularly inventive nature of using gamma cyclodextrin to complex B(a)P.
  • cyclodextrin-cellulose derivatives remove B(a)P in an aqueous environment.
  • Examples 1-3 describe methods to provide inventive materials, and the following Examples 4-8 demonstrate a few of the ways in which the inventive materials can be incorporated in products.
  • Smokeless tobacco for oral administration is provided.
  • a commercial blend of tobaccos can be cut to the suitable size and shape for a loose leaf chewing tobacco product.
  • the cut tobacco can then be cased with an aqueous mixture of flavouring materials and sweetening agents to give a cut and cased tobacco containing approximately 50 percent moisture.
  • the treated tobacco can be arranged on a conveyor belt or loaded onto sheets and moved through or placed in a dryer.
  • the dryer may heat the tobacco to about 70°C, briefly, to reduce its moisture content to about 25 percent.
  • Subsequent processing of the tobacco can be conventional such as application of a top flavouring solution and temporary storage to allow equilibration of the top flavouring additives throughout the tobacco mass.
  • Top flavouring can serve the dual purpose of both adding a top note to the tobacco itself and presenting a number of unassociated flavour molecules in the mixture. These molecules could be expected to migrate toward cyclodextrins provided in proximity to the flavoured tobacco and complex with them. Moist conditions favour the formation of an equilibration throughout the tobacco mass and nearby cellulosic material comprising cyclodextrins.
  • flavourant- complexed cyclodextrins previously complexed with flavourant can be provided.
  • flavourant- complexed cyclodextrins it can be found that flavourant migration occurs in two directions: some of the complexed flavourant will disassociate and migrate toward the tobacco whereas certain of the tobacco-associated flavourant will complex with the recently-emptied cyclodextrins.
  • fibrous cellulosic material is dipped in a water bath containing 15 mM ⁇ -cyclodextrin and 15 mM imidazolidone. After dipping it is subjected to oven hearting at 150 0 C for 1-5 minutes. Where ⁇ -cyclodextrin is used, one may increase the concentration to about 130 mM and where ⁇ -cyclodextrin is used, to about 170 mM.
  • the procedure results in cyclodextrin linked with imidazolidone (spacer group) through the formation of ether (hemiacetal) bonds between the imidazolidone and the hydroxyl group (s) on the cyclodextrin.
  • the imidazolidone is attached to the cellulose by the formation of ether bonds between it and hydroxyl groups present on the cellulose.
  • cellulosic material is provided having a covalently bonded spacer group which in turn is linked to a cyclodextrin.
  • the cyclodextrin-cellulosic material is cut to approximately the same size as the tobacco pieces and blended with the tobacco. Moisture, pH, and other parameters are adjusted as necessary to provide a stable, useable product. For example, buffering agents may be used to produce a pH of above about 6.5, or above about 7.5. The blend is packaged into moisture proof containers. _ _
  • This embodiment of the invention comprises a pouch-type product which can be similar to portioned Swedish-style snus products. That is, as a pouch containing tobacco products intended to fit into the gingival fold of the mouth.
  • a non-woven fabric can be used as a package material for such pouches.
  • cyclodextrin derivatised with a spacer group having a reactive entity at the non-cyclodextrin end of the spacer group is obtained (for example, monochlorotriazinyl- ⁇ -cyclodextrin, Wacker GmbH, Germany).
  • the reactive entity is allowed to interact with the fabric thus bonding the spacer group to the fabric.
  • a unit of pulverized tobacco suitable for an individual dose for example 0.05-2.0 g (dry weight) is placed on the cellulose-bonded fabric and a pouch is formed.
  • pieces of cellulosic material incorporating cyclodextrins may be blended with the tobacco prior to its addition to the pouch.
  • Conventional snus or tea bag filling equipment may be used.
  • the pouch may be sealed shut, for example by heat sealing. Where different cellulosic materials are substituted, e.g., long fibre cellulose materials, a heat weldable binder may be added to the material to facilitate heat sealing.
  • the product is stored in a moisture-proof container, possibly under refrigeration, prior to use.
  • a mini snus product typically contains 0.5 g tobacco.
  • a mini snus product typically contains 0.5 g tobacco.
  • benzo(a)pyrene present in that dose of tobacco 1.9-19 mg ⁇ - cyclodextrin (MW 972) could be attached to the fabric.
  • cyclodextrin (MW 1135) could be attached to the fabric.
  • 2.6-26 mg of ⁇ -cyclodextrin MW 1297 could be attached to the fabric.
  • a mix of two or more cyclodextrins could be employed.
  • cyclodextrin derivatised with a spacer group having a reactive entity at the non-cyclodextrin end of the spacer group is obtained (for example, CAVAMAX W7 CITRAL, Wacker GmbH, Germany).
  • This reactive entity is designed to react with cellulose wherein the spacer group is bonded to the cellulosic material and provides a lemon flavourant to the resultant product.
  • a sheet of cellulosic material in web form is used.
  • tobacco extracts are applied to cellulosic or synthetic tobacco-like material which is then incorporated into a pouch-like object formed by folding the sheet of cellulosic web around the cellulosic or tobacco-like material.
  • a pouch so provided does not contain whole, natural tobacco but rather natural or synthetic tobacco extracts.
  • moisture permeating the pouch will encourage the lemon flavourant to disassociate from the cyclodextrin and pass out of the pouch and into the surrounding area.
  • molecules present in the extracts or formed by the extract when moistened are transported with the moisture through the sheet of cellulosic material are attracted to the relatively hydrophobic inner cavities of the cyclodextrins, thus prevented from exiting the pouch or from remaining in the pouch unbound.
  • Example 7 Smokeless Oral Tobacco Product Comprising Cellulosic Wrapper
  • a unit of cellulosic material in web form is provided. 4-40 mg of ⁇ -cyclodextrin is bound to the cellulosic web. 1.0 g of standard smokeless tobacco is placed on the cellulosic web and a sealed pouch is formed. _ _
  • the amount of ⁇ -cyclodextrins is selected to correspond to this amount.
  • an amount of cadmium is released from the tobacco product, a portion of which will be subsequently bound by the ⁇ -cyclodextrins.
  • Cadmium exposure may be disfavoured; complexation by ⁇ -cyclodextrins will reduce the user's exposure to the substance.
  • the most common oxidation state of cadmium is +2, therefore cadmium is at times represented as cadmium(II). Any state and any form of cadmium could be encompassed by the present invention.
  • a sheet of cellulosic material in web form is provided, a spacer gf oup and subsequently a cyclodextrin derivative are bound to the cellulosic web.
  • the cellulosic web is treated with a mixture of nicotine and flavourants to provide nicotine- and flavourant-cyclodextrin inclusion complexes.
  • a suitable amount of tobacco in the desired physical form is added to the sheet, which is then folded to form a pouch and sealed.
  • moisture permeating the pouch will encourage the nicotine and flavourant to disassociate from the cyclodextrin and pass out of the pouch.
  • Compounds present in or formed by the tobacco are similarly transported by moisture towards the outside of the pouch, however, due to the suitably-sized, relatively hydrophobic cavity offered by the bound cyclodextrin they are drawn into an inclusion complex and do not pass out of the pouch.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EP08702112A 2007-01-17 2008-01-16 Tabakprodukt sowie herstellung und verwendungen davon Not-in-force EP2101598B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0700889.9A GB0700889D0 (en) 2007-01-17 2007-01-17 Tobacco, tobacco derivative and/or tobacco substitute products, preparation and uses thereof
PCT/GB2008/050029 WO2008087449A2 (en) 2007-01-17 2008-01-16 Tobacco product, preparation and uses thereof

Publications (2)

Publication Number Publication Date
EP2101598A2 true EP2101598A2 (de) 2009-09-23
EP2101598B1 EP2101598B1 (de) 2011-09-28

Family

ID=37810092

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08702112A Not-in-force EP2101598B1 (de) 2007-01-17 2008-01-16 Tabakprodukt sowie herstellung und verwendungen davon

Country Status (11)

Country Link
US (1) US20100126520A1 (de)
EP (1) EP2101598B1 (de)
JP (1) JP5178741B2 (de)
AT (1) ATE525920T1 (de)
AU (1) AU2008206820B2 (de)
CA (1) CA2674556A1 (de)
DK (1) DK2101598T3 (de)
GB (1) GB0700889D0 (de)
NZ (1) NZ577848A (de)
WO (1) WO2008087449A2 (de)
ZA (1) ZA200904362B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001186A (zh) * 2015-06-25 2015-10-28 云南中烟工业有限责任公司 烟草中一种异戊烯基苯并内酯类化合物的制备方法和应用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101715650B1 (ko) * 2009-05-29 2017-03-13 가부시키가이샤 이노악 기술 연구소 첩부재
EP2443943A4 (de) * 2009-06-16 2014-09-03 Japan Tobacco Inc Orales tabakprodukt
CN102754907B (zh) 2012-01-20 2015-06-24 奥驰亚客户服务公司 口腔用产品
US9854831B2 (en) 2012-01-20 2018-01-02 Altria Client Services Llc Oral product
CN103039688B (zh) 2012-01-20 2016-01-06 奥驰亚客户服务公司 口腔用产品
CN102754908B (zh) 2012-01-20 2015-06-10 奥驰亚客户服务公司 口腔用烟草产品
US9420825B2 (en) * 2012-02-13 2016-08-23 R.J. Reynolds Tobacco Company Whitened tobacco composition
US20160157515A1 (en) * 2014-12-05 2016-06-09 R.J. Reynolds Tobacco Company Smokeless tobacco pouch
US20180271146A9 (en) * 2015-04-17 2018-09-27 Swedish Match North Europe Ab Oral pouched product having a rectangular shape
CN105017190B (zh) * 2015-06-25 2017-09-26 云南中烟工业有限责任公司 烟草中一种苯并内酯类化合物的制备方法和应用
CN104945360B (zh) * 2015-06-25 2017-05-10 云南中烟工业有限责任公司 烟草中一种苯丙素类化合物的制备方法和应用
US20170188622A1 (en) * 2016-01-05 2017-07-06 R.J. Reynolds Tobacco Company Smokeless tobacco product
CN105646411B (zh) * 2016-03-30 2018-07-24 云南中烟工业有限责任公司 一种2-羧基呋喃类化合物、其制备方法及其抗菌活性的应用
GB201718033D0 (en) * 2017-11-01 2017-12-13 Nicoventures Holdings Ltd Flavoured vaporisable formulation
GB2569940B (en) * 2017-11-01 2022-10-19 Nicoventures Trading Ltd Aerosolisable formulation
US11083765B2 (en) * 2017-12-15 2021-08-10 Andrew Scott Davis Hemp leaf chew composition and method for producing
KR20200005074A (ko) * 2018-07-05 2020-01-15 주식회사 케이티앤지 향미 성분을 포함하는 흡연 물품 및 향미 화합물을 제조하는 방법
CN109181869A (zh) * 2018-09-29 2019-01-11 中国烟草总公司郑州烟草研究院 一种烟用焦甜香香精
GB201817863D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817859D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817865D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
CN109602069B (zh) * 2018-12-03 2021-07-09 云南中烟工业有限责任公司 一种烟草发烟芯材发烟剂的制备方法及应用
JP2022547977A (ja) 2019-09-11 2022-11-16 ニコベンチャーズ トレーディング リミテッド タバコを白色化するための代替方法
US11369131B2 (en) 2019-09-13 2022-06-28 Nicoventures Trading Limited Method for whitening tobacco
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11872231B2 (en) * 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11937626B2 (en) 2020-09-04 2024-03-26 Nicoventures Trading Limited Method for whitening tobacco

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3047431A (en) * 1961-05-08 1962-07-31 Philip Morris Inc Smoking composition
JPS50125100A (de) * 1974-03-19 1975-10-01
JPS5132799A (ja) * 1974-09-13 1976-03-19 Toyo Ink Mfg Co Tabakonokemuryofuirutaa
HU181733B (en) * 1980-08-07 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing sorbents containing cyclodextrin on cellulose base
SE8904295D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Smoking substitute
US5512306A (en) * 1992-06-19 1996-04-30 Pharmica Ab Smoking substitute
SE9002052D0 (sv) * 1990-06-08 1990-06-08 Pharmacia Ab Smoking composition
US5144964A (en) * 1991-03-14 1992-09-08 Philip Morris Incorporated Smoking compositions containing a flavorant-release additive
FR2675347B1 (fr) * 1991-04-17 1994-09-02 Tabacs & Allumettes Ind Cigarette a papier incorporant un agent modificateur de la fumee.
JPH065496U (ja) * 1992-06-29 1994-01-25 株式会社ホウセン商会 包装噛煙草
US6120946A (en) * 1994-10-17 2000-09-19 Corning Incorporated Method for printing a color filter
US6152033A (en) * 1997-08-29 2000-11-28 Corning Incorporated Method of making an electronic printed structure
US5891697A (en) * 1997-09-25 1999-04-06 Washington State University Research Foundation Monoterpene synthases from common sage (Salvia officinalis)
US6671034B1 (en) * 1998-04-30 2003-12-30 Ebara Corporation Microfabrication of pattern imprinting
US7032601B2 (en) * 2001-09-28 2006-04-25 U.S. Smokeless Tobacco Company Encapsulated materials
DE10155781A1 (de) * 2001-11-14 2003-05-22 Deutsches Textilforschzentrum Verfahren zur Herstellung von reaktiven Cyclodextrinen, ein damit ausgerüstetes textiles Material und deren Verwendung
JP2005526111A (ja) * 2002-04-22 2005-09-02 ザ プロクター アンド ギャンブル カンパニー 亜鉛イオノフォア性を有する物質の使用
DE10240105B4 (de) * 2002-08-30 2005-03-24 Infineon Technologies Ag Herstellung organischer elektronischer Schaltkreise durch Kontaktdrucktechniken
US20040129280A1 (en) * 2002-10-31 2004-07-08 Woodson Beverley C. Electrically heated cigarette including controlled-release flavoring
JP4317375B2 (ja) * 2003-03-20 2009-08-19 株式会社日立製作所 ナノプリント装置、及び微細構造転写方法
US6861520B1 (en) * 2003-04-30 2005-03-01 Dan River, Inc. Process for chemically bonding an odor-encapsulating agent to textiles and textiles formed by the process
CN102669810B (zh) * 2003-11-07 2014-11-05 美国无烟烟草有限责任公司 烟草组合物
US7950399B2 (en) * 2005-04-29 2011-05-31 Philip Morris Usa Inc. Non-tobacco pouch product

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008087449A3 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105001186A (zh) * 2015-06-25 2015-10-28 云南中烟工业有限责任公司 烟草中一种异戊烯基苯并内酯类化合物的制备方法和应用

Also Published As

Publication number Publication date
WO2008087449A2 (en) 2008-07-24
DK2101598T3 (da) 2011-12-12
JP2010516243A (ja) 2010-05-20
CA2674556A1 (en) 2008-07-24
GB0700889D0 (en) 2007-02-21
ZA200904362B (en) 2010-03-31
US20100126520A1 (en) 2010-05-27
ATE525920T1 (de) 2011-10-15
AU2008206820A1 (en) 2008-07-24
WO2008087449A3 (en) 2008-10-30
JP5178741B2 (ja) 2013-04-10
NZ577848A (en) 2012-01-12
EP2101598B1 (de) 2011-09-28
AU2008206820B2 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
EP2101598B1 (de) Tabakprodukt sowie herstellung und verwendungen davon
CA3006621C (en) Tobacco composition
DK2377413T3 (en) Smokeless tobacco compositions and methods of treating tobacco for use therein
CA3150120A1 (en) SACHET PRODUCTS WITH ENHANCED FLAVOR STABILITY
DK2173200T3 (en) Smokeless tobacco compositions and methods of treating tobacco for use therein
US8361236B2 (en) Supramolecular complex flavor immobilizing for controlled release of flavor in smoking articles
EP2352395A2 (de) Tabakprodukte und verfahren
US20210068446A1 (en) Oral product with cellulosic flavor stabilizer
CA3156573A1 (en) Oral product and method of manufacture
CN112674345A (zh) 一种环糊精添加剂及其制备方法和应用
JPWO2011114528A1 (ja) シガレットパッケージ
EP2552250B1 (de) Aromaimmobilisierung eines supramolekularen komplexes und kontrollierte freisetzung
JP2012029637A (ja) 喫煙物品
JP2021510297A (ja) 喫煙品に含有させるための材料
TWI816402B (zh) 減少煙味的吸煙製品及其製備方法
WO2023112920A1 (ja) たばこ材料およびその製造方法、並びにたばこ製品
CHULURKS et al. Preservation of nicotine and solanesol from tobacco by cyclodextrins nanoencapsulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090604

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008010125

Country of ref document: DE

Effective date: 20111222

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20110928

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20110928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111229

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 525920

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120128

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120130

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120131

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20120629

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120116

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120928

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008010125

Country of ref document: DE

Effective date: 20120629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120131

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120131

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110928

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20140121

Year of fee payment: 7

Ref country code: SE

Payment date: 20140121

Year of fee payment: 7

Ref country code: DE

Payment date: 20140122

Year of fee payment: 7

Ref country code: NO

Payment date: 20140114

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080116

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008010125

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20150131

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150801

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150131